공시 • Jun 05
Basel Medical Group Ltd Announces CFO Changes The Board of Directors of Basel Medical Group Ltd. has appointed Mr. Neo Chun How Alton as its new interim Chief Financial Officer effective June 2, 2026. Mr. Neo was appointed as interim CFO to replace Ms. Jianing Lu, the CFO of the Company. Ms. Lu resigned from her position as CFO of the Company. Mr. Neo is a finance professional with extensive experience in corporate leadership, financial management, and education. Prior to joining Basel Medical, Alton served as the deputy CEO of InCorp Global's Singapore operations, where he oversaw the entire Singapore's operations - in particular, advisory and outsourcing services. In this role, he provides expertise in management reporting, corporate restructuring, business valuation, insolvency, and forensic accounting. Before his tenure at InCorp Global, Mr. Neo contributed to the Singapore Ministry of Finance as a tax policy associate, focusing on the development and review of tax incentives. He was also part of the pioneer team at the Singapore Accountancy Commission (now ACRA) that developed the Singapore Chartered Accountant Qualification Programme. In addition to his corporate roles, Mr. Neo is dedicated to education, having developed and taught courses in financial accounting and related subjects at leading tertiary institutions. Currently, he serves as a part-time tutor at the London School of Business & Finance in Singapore and Singapore University of Social Sciences. Mr. Neo holds a Master of Business Administration, University of Hull and is also a Chartered Valuer, Institute of Valuers and Appraisers, CA Singapore, Institute of Singapore Chartered Accountants and CPA Australia. Reported Earnings • Mar 17
Full year 2025 earnings released: S$0.64 loss per share (vs S$0.13 profit in FY 2024) Full year 2025 results: S$0.64 loss per share (down from S$0.13 profit in FY 2024). Revenue: S$12.1m (up 16% from FY 2024). Net loss: S$12.1m (down S$14.2m from profit in FY 2024). Board Change • Jan 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Group CFO & Director Jianing Lu is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • Dec 04
Basel Medical Group Receives Delinquency Notification from Nasdaq Basel Medical Group Ltd. announced that it has received notification from Nasdaq that the Company’s annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company’s auditor, NLA DFK Assurance PAC, on the Company’s financial statements. Pursuant to Listing Rule 5250(c)(1), companies shall timely file all required periodic financial reports with the United States Securities and Exchange Commission, and annual reports filed shall contain audited financial statements. Under Nasdaq rules, the Company now has 60 calendar days to submit a plan to regain compliance and if such plan is accepted by Nasdaq, an exception of up to 180 calendar days from the original filing’s due date may be granted, or until May 18, 2026, to regain compliance. In determining whether to accept such plan, Nasdaq will consider such things as the likelihood that the filing, along with any subsequent periodic filing that will be due, can be made within the 180 day period, the Company’s past compliance history, the reasons for the late filing, other corporate events that may occur within review period, the Company’s overall financial condition and its public disclosures. Any subsequent periodic filing that is due within the 180 day exception period must be filed no later than the end of the period. If the plan to regain compliance is not accepted, the Company will have the opportunity to appeal that decision to a Hearings Panel. The Company is currently working with its accounting, audit and legal professionals to prepare a rectification plan to remedy the above mentioned non-compliance. Trading of the Company’s shares on Nasdaq is not currently affected by such non-compliance. 공시 • Oct 28
Basel Medical Group Ltd announced delayed 20-F filing On 10/27/2025, Basel Medical Group Ltd announced that they will be unable to file their next 20-F by the deadline required by the SEC. Reported Earnings • Jun 20
First half 2025 earnings released: S$0.02 loss per share (vs S$0.082 profit in 1H 2024) First half 2025 results: S$0.02 loss per share (down from S$0.082 profit in 1H 2024). Revenue: S$5.04m (down 1.0% from 1H 2024). Net loss: S$317.0k (down 124% from profit in 1H 2024). New Risk • Jun 18
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (62% average daily change). High level of non-cash earnings (21% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (4.2% net profit margin). Market cap is less than US$100m (US$50.9m market cap). Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorates as stock falls 35% After last week's 35% share price decline to US$3.93, the stock trades at a trailing P/E ratio of 45.9x. Average trailing P/E is 21x in the Healthcare industry in the US. Buy Or Sell Opportunity • May 30
Now 128% overvalued after recent price rise Over the last 90 days, the stock has risen 46% to US$6.08. The fair value is estimated to be US$2.66, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.3% over the last year. Earnings per share has grown by 16%. Valuation Update With 7 Day Price Move • May 23
Investor sentiment deteriorates as stock falls 42% After last week's 42% share price decline to US$1.37, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 18x in the Healthcare industry in the US. Buy Or Sell Opportunity • May 14
Now 28% undervalued The stock has been flat over the last 90 days, currently trading at US$1.90. The fair value is estimated to be US$2.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.3% over the last year. Earnings per share has grown by 16%. Valuation Update With 7 Day Price Move • May 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$4.80, the stock trades at a trailing P/E ratio of 56x. Average trailing P/E is 20x in the Healthcare industry in the US. Board Change • May 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Group CFO & Director Jianing Lu is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$4.88, the stock trades at a trailing P/E ratio of 58.4x. Average trailing P/E is 24x in the Healthcare industry in the US. 공시 • Feb 26
Basel Medical Group Ltd has completed an IPO in the amount of $8.82 million. Basel Medical Group Ltd has completed an IPO in the amount of $8.82 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,205,000
Price\Range: $4
Discount Per Security: $0.28